161 related articles for article (PubMed ID: 21729979)
21. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Confavreux C; Vermersch P; Simu M; Sindic C; Hupperts R; Bajenaru O; Edan G; Grimaldi L; Marginean I; Medaer R; Orefice G; Pascu I; Pelletier J; Sanders E; Scarpini E; Mancardi GL
Mult Scler; 2009 Feb; 15(2):238-43. PubMed ID: 18987103
[TBL] [Abstract][Full Text] [Related]
22. [Nicolau syndrome after administration of glatiramer acetate].
Pulido Pérez A; Parra Blanco V; Suárez Fernández R
Neurologia; 2013 Sep; 28(7):448-9. PubMed ID: 22698594
[No Abstract] [Full Text] [Related]
23. Allergy workup in immediate-type local reactions to glatiramer acetate.
Sánchez-López J; Rodríguez del Rio P; Cases-Ortega B; Martínez-Cócera C; Fernández-Rivas M
J Investig Allergol Clin Immunol; 2010; 20(6):521-3. PubMed ID: 21243937
[TBL] [Abstract][Full Text] [Related]
24. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
[TBL] [Abstract][Full Text] [Related]
25. Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate.
Pardo G; Boutwell C; Conner J; Denney D; Oleen-Burkey M
J Neurosci Nurs; 2010 Feb; 42(1):40-6. PubMed ID: 20187348
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients.
Vallittu AM; Peltoniemi J; Elovaara I; Kuusisto H; Färkkilä M; Multanen J; Erälinna JP
Acta Neurol Scand; 2005 Oct; 112(4):234-7. PubMed ID: 16146492
[TBL] [Abstract][Full Text] [Related]
27. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
Johnson KP; Ford CC; Lisak RP; Wolinsky JS
Acta Neurol Scand; 2005 Jan; 111(1):42-7. PubMed ID: 15595937
[TBL] [Abstract][Full Text] [Related]
28. [Emerging new therapies for relapsing remitting multiple sclerosis].
Anis S; Achiron A
Harefuah; 2014 Nov; 153(11):658-62, 687, 686. PubMed ID: 25563027
[TBL] [Abstract][Full Text] [Related]
29. Recalcitrant allergic contact dermatitis from azathioprine tablets.
Lauerma AI; Koivuluhta M; Alenius H
Contact Dermatitis; 2001 Feb; 44(2):129. PubMed ID: 11205401
[No Abstract] [Full Text] [Related]
30. Allergic contact dermatitis caused by tetracaine contained in otic drops.
García-Gavín J; Alonso-González J; Gutiérrez-González E; Álvarez-Pérez A; Fernández-Redondo V; Toribio J
Contact Dermatitis; 2011 Sep; 65(3):175-6. PubMed ID: 21827509
[No Abstract] [Full Text] [Related]
31. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
32. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
Miller A; Spada V; Beerkircher D; Kreitman RR
Mult Scler; 2008 May; 14(4):494-9. PubMed ID: 18208875
[TBL] [Abstract][Full Text] [Related]
33. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
34. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
[TBL] [Abstract][Full Text] [Related]
35. Successful Rapid Desensitization to Glatiramer Acetate in a Patient With Multiple Sclerosis.
Syrigou E; Psarros P; Grapsa D; Syrigos K
J Investig Allergol Clin Immunol; 2015; 25(3):214-5. PubMed ID: 26182688
[No Abstract] [Full Text] [Related]
36. [Rare and clinically relevant adverse reactions following subcutaneous administration of glatiramer acetate].
Sevilla Ortiz M; Martínez Martínez L; Piñeiro Corrales G
Farm Hosp; 2011; 35(3):160-1. PubMed ID: 21441052
[No Abstract] [Full Text] [Related]
37. [Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1 (Glatiramer acetate)].
Gaudez C; Regnier S; Aractingi S; Heinzlef O
Rev Neurol (Paris); 2003 May; 159(5 Pt 1):571-3. PubMed ID: 12773903
[TBL] [Abstract][Full Text] [Related]
38. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
39. IgE-mediated allergic reactions after the first administration of glatiramer acetate in patients with multiple sclerosis.
Corominas M; Postigo I; Cardona V; Lleonart R; Romero-Pinel L; Martinez J
Int Arch Allergy Immunol; 2014; 165(4):244-6. PubMed ID: 25634237
[TBL] [Abstract][Full Text] [Related]
40. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
